A Single-centre, Parallel-cohort, Randomized, Open-label, Two-period, Cross-over, Bioequivalence Study of the Fixed Dose Combination of HR20033 Relative to Co-administration of the Individual Components in Two Cohorts of Healthy Chinese Subjects in the Fed State
Latest Information Update: 07 Nov 2023
At a glance
- Drugs Henagliflozin (Primary) ; Henagliflozin/metformin (Primary) ; Metformin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Shandong Suncadia Medicine
- 12 Nov 2021 New trial record